ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Epinephrine

Also written as “epinephrine inhalation aerosol”, “Epinephrine Nasal Spray, 2.5 mg” and “Epinephrine Nasal Spray, 5.25 mg”.

Its studies are mostly in Anaphylaxis · Asthma · Hypersensitivity · Chronic Urticaria · Respiratory Tract Infections, led by 7 companies.

Drug pageEpinephrine: every studyMany companies study it; this page follows only the 16 they lead. All 221 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Dec 19, 201916 company-led studies, 5 open or runningNext primary completion: Apr 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amphastar Pharmaceuticalsits history only40 open or runningphase 4since Dec 19, 2019Jun 7, 2010none ahead
Nasus Pharmaits history only42 open or runningphase 3since Jun 8, 2025Dec 1, 2020none ahead
ARS Pharmaceuticals32 open or runningphase 4since Feb 18, 2025Jun 9, 2021Apr 2027phase 4 · NCT06834165
De Motu Cordisits history only20 open or runningphase 1since Nov 9, 2021Nov 9, 2021none ahead
ALK-Abellóits history only10 open or runningphase 4since Jun 20, 2013Jun 20, 2013none ahead
Hikma Pharmaceuticalsits history only11 open or runningphase 2since Aug 18, 2026Aug 18, 2026May 8, 2027phase 2 · NCT07891780
Smith & Nephewits history only10 open or runningphase 2since Apr 5, 2017Apr 5, 2017none ahead

Also a collaborator on its studies: Medistat Ltd., Israel, Pharma Medica Research and Novotech (Australia) Pty.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ARS Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2021First study: phase 1 study in Respiratory Tract InfectionsFirst studyNCT04930900 · 15 enrolled · Australia
  2. Feb 18, 2025Phase 4 study in HypersensitivityNCT06834165 · 600 planned · United States
  3. Apr 4, 2025Phase 2 study in Chronic UrticariaNCT06927999 · 42 planned · United States, Germany

Ahead

  1. Apr 2027Primary completion: phase 4 study in HypersensitivityNCT06834165
  2. Jun 2027Primary completion: phase 2 study in Chronic UrticariaNCT06927999

TargetBeta

“Adrenergic receptor agonist; Adrenergic receptor agonist”ChEMBL 37, by rule

Studies

All 3 ARS Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06927999Chronic Urticaria · United States, Germany2RecruitingJun 202742
NCT06834165Hypersensitivity · United States4RecruitingApr 2027600
NCT04930900Respiratory Tract Infections · Australia1CompletedMar 31, 202215

How it is read

Names in the registry

  • “epinephrine inhalation aerosol”, 4 entries
  • “Epinephrine Nasal Spray, 2.5 mg”, 1 entry
  • “Epinephrine Nasal Spray, 5.25 mg”, 1 entry
  • “0.5 mg epinephrine”, 1 entry
  • “1 mg epinephrine”, 1 entry

Codes read as this program: FMXIN002.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.